With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Roche is stepping up the defence of its eye franchise, but the real test will come with pivotal readouts for its new contender versus Regeneron’s Eylea.
Allergan's wet AMD candidate abicipar has apparently succeeded in phase III – but a safety signal could make it hard to compete against Regeneron's Eylea.